NCT01597739View on ClinicalTrials.gov

A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions

Arthritis, Rheumatoid

Interventions

DRUG

JNJ-40346527

Type=exact number; unit=mg; number=100, form=capsule; route=oral use; twice daily.

DRUG

Placebo

Form=capsule; route=oral use; twice daily.

Trial Locations (32)

Unknown

Buenos Aires

San Juan

San Miguel de Tucumán

Plovdiv

Sevlievo

Veliko Tarnovo

Providencia

Santiago

Prague

Slaný

Budapest

Hatvan

Szikszó

Elblag

Poznan

Warsaw

Kazan'

Moscow

Novosibirsk

Petrozavodsk

Saint Petersburg

Ulyanovsk

Yaroslavl

Singapore

Gwangju

Seoul

Suwon

Donetsk

Kharkiv

Ternopil

Vinnitsa

Zaporizhzhya

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT01597739 - A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy | Biotech Hunter | Biotech Hunter